levetiracetam (keppra): evidence-based polypharmacy in two patients with epilepsy

Introduction: epilepsy is a prolonged disorder characterized by repeated violent epileptic seizures. its managements depend on proper classification of the seizure category and the epileptic pattern. levetiracetam (keppra®) has been approved as monotherapy or for adjunctive management of partial onset seizures, juvenile myoclonic epilepsy, and idiopathic generalized epilepsy. case reporting of levetiracetam polypharmacy shows adverse effects linked to evidence-based clinical and laboratory data in two patients with epilepsy. case reporting of levetiracetam polypharmacy, based on evidence-based clinical and laboratory data was of interest that investigated. case presentation: two cases were studied, one patient was a 32-year-old male and the other was a 14-year-old female. the key words relevant to search topics were surveyed using pubmed (united states national library of medicine). articles related to the levetiracetam prescription in epileptic patients were selected and considered separately. pharmacotherapy based on levetiracetam, primidone, phenytoin, and topiramate in a 32-year-old epileptic male showed a decrease in white blood cell count (3400 cells/mcl), red blood cell count (4.4 mil/mm³) hemoglobin (11.8 g/dl) and hematocrit (36.7%). the drug regimen for the 14-year-old epileptic female was a levetiracetam polypharmacy in combination with primidone and sodium-valproate simultaneously. in this patient, there was a decrease in hemoglobin (10.4 g/dl) and hematocrit (34%). an increase in lymphocyte (84%) was also observed. conclusions: administration of aeds in general and levetiracetam in particular should be based on attention to pharmacokinetic behavior in terms of monotherapy or polypharmacy.